Patient characteristics
| . | Total (N = 148), n (%) or median [range] . | Maintenance MTX (n = 37), n (%) or median [range] . | Auto-SCT (n = 70), n (%) or median [range] . | P value . |
|---|---|---|---|---|
| Age, y | 66 [29-85] | 72 [46-85] | 62 [29-75] | .076 |
| >60 | 103 (69.6%) | 32 (86.5%) | 45 (64.3%) | |
| >70 | 48 (32.4%) | 20 (54.1%) | 11 (15.7%) | <.001∗ |
| Sex, female | 75 (50.7%) | 23 (62.2%) | 35 (50.0%) | .144 |
| Race, White | 141 (95.3%) | 37 (100.0%) | 66 (94.3%) | .070∗ |
| ECOG PS | .109 | |||
| 0-1 | 93 (62.8%) | 22 (59.5%) | 50 (71.4%) | |
| ≥2 | 55 (37.2%) | 15 (40.5%) | 20 (28.6%) | |
| KPS | .024∗ | |||
| ≥70 | 97 (71.9%) | 22 (66.7%) | 54 (83.1%) | |
| <70 | 38 (28.1%) | 11 (33.3%) | 11 (16.9%) | |
| LDH, >ULN | 73 (49.3%) | 17 (45.9%) | 27 (38.6%) | .012∗ |
| Albumin, <4 | 50 (51.5%) | 16 (64%) | 19 (36.5%) | .009∗ |
| CSF involvement | 9 (6.1%) | 4 (10.8%) | 4 (5.7%) | .419 |
| Vitreoretinal involvement | 15 (10.1%) | 6 (16.2%) | 4 (5.7%) | .144 |
| Deep brain involvement | 100 (69.9%) | 27 (75.0%) | 45 (66.2%) | .380 |
| Multifocal disease | 89 (60.1%) | 23 (62.2%) | 44 (62.9%) | .749 |
| 0-1 IELSG† (low) | .094 | |||
| 2-3 (intermediate) | 28 (21.5%) | 6 (17.6%) | 12 (18.5%) | |
| 4-5 (high) | 85 (65.4%) | 20 (58.8%) | 48 (73.8%) | |
| 17 (13.1%) | 8 (23.5%) | 5 (7.7%) | ||
| MSKCC‡ | .026∗ | |||
| Class 1 (age <50, any KPS) | 17 (12.4%) | 1 (3.0%) | 7 (10.6%) | |
| Class 2 (age ≥50, KPS ≥70) | 85 (62.0%) | 21 (63.6%) | 48 (72.7%) | |
| Class 3 (age ≥50, KPS <70) | 35 (25.5%) | 11 (33.3%) | 11 (16.7%) | |
| Induction regimen | .004∗ | |||
| MRT | 117 (79.1%) | 24 (64.9%) | 64 (91.4%) | |
| MR | 31 (20.9%) | 13 (35.1%) | 6 (8.6%) |
| . | Total (N = 148), n (%) or median [range] . | Maintenance MTX (n = 37), n (%) or median [range] . | Auto-SCT (n = 70), n (%) or median [range] . | P value . |
|---|---|---|---|---|
| Age, y | 66 [29-85] | 72 [46-85] | 62 [29-75] | .076 |
| >60 | 103 (69.6%) | 32 (86.5%) | 45 (64.3%) | |
| >70 | 48 (32.4%) | 20 (54.1%) | 11 (15.7%) | <.001∗ |
| Sex, female | 75 (50.7%) | 23 (62.2%) | 35 (50.0%) | .144 |
| Race, White | 141 (95.3%) | 37 (100.0%) | 66 (94.3%) | .070∗ |
| ECOG PS | .109 | |||
| 0-1 | 93 (62.8%) | 22 (59.5%) | 50 (71.4%) | |
| ≥2 | 55 (37.2%) | 15 (40.5%) | 20 (28.6%) | |
| KPS | .024∗ | |||
| ≥70 | 97 (71.9%) | 22 (66.7%) | 54 (83.1%) | |
| <70 | 38 (28.1%) | 11 (33.3%) | 11 (16.9%) | |
| LDH, >ULN | 73 (49.3%) | 17 (45.9%) | 27 (38.6%) | .012∗ |
| Albumin, <4 | 50 (51.5%) | 16 (64%) | 19 (36.5%) | .009∗ |
| CSF involvement | 9 (6.1%) | 4 (10.8%) | 4 (5.7%) | .419 |
| Vitreoretinal involvement | 15 (10.1%) | 6 (16.2%) | 4 (5.7%) | .144 |
| Deep brain involvement | 100 (69.9%) | 27 (75.0%) | 45 (66.2%) | .380 |
| Multifocal disease | 89 (60.1%) | 23 (62.2%) | 44 (62.9%) | .749 |
| 0-1 IELSG† (low) | .094 | |||
| 2-3 (intermediate) | 28 (21.5%) | 6 (17.6%) | 12 (18.5%) | |
| 4-5 (high) | 85 (65.4%) | 20 (58.8%) | 48 (73.8%) | |
| 17 (13.1%) | 8 (23.5%) | 5 (7.7%) | ||
| MSKCC‡ | .026∗ | |||
| Class 1 (age <50, any KPS) | 17 (12.4%) | 1 (3.0%) | 7 (10.6%) | |
| Class 2 (age ≥50, KPS ≥70) | 85 (62.0%) | 21 (63.6%) | 48 (72.7%) | |
| Class 3 (age ≥50, KPS <70) | 35 (25.5%) | 11 (33.3%) | 11 (16.7%) | |
| Induction regimen | .004∗ | |||
| MRT | 117 (79.1%) | 24 (64.9%) | 64 (91.4%) | |
| MR | 31 (20.9%) | 13 (35.1%) | 6 (8.6%) |